Baroldi Joseph 4

What Happened

• Joseph Baroldi, Executive Vice President and Chief Business Officer of Ionis Pharmaceuticals (IONS), sold 1,626 shares on April 28, 2026. The reported weighted-average sale price was $71.79, generating roughly $116,727 in proceeds. This was a sale (not a purchase).

Key Details

• Transaction date: 2026-04-28; filing date: 2026-04-30 (filed within the standard two-business-day Form 4 window).
• Price: weighted average $71.79; sales occurred at prices ranging from $71.67 to $71.825 across multiple trades.
• Shares sold: 1,626; total reported proceeds: $116,727.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes: Sales were made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Baroldi on November 25, 2025. The filer notes they can provide a breakdown of the number of shares sold at each separate price within the reported range upon request.

Context

• This was a planned sale under a 10b5-1 plan, which typically indicates pre-scheduled, non-discretionary trades rather than a real-time directional bet by the insider. Sales are common and do not necessarily signal changed views on the company; purchases generally carry more informational weight for investors.